German HTA: Benefits of Roche's Perjeta are restricted
This article was originally published in Scrip
Executive Summary
July has so far proved a mixed bag for Roche's HER2 breast cancer drug Perjeta (pertuzumab). German HTA authorities have indicated it offers additional benefit over comparators for some patients with advanced disease, but not for many others, which will likely impact the drug's reimbursement price. Meanwhile, the US FDA has granted a priority review for the drug to be used in patients with earlier stage breast cancer before surgery.